• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

主要术后并发症对卵巢癌细胞减灭术后复发和长期生存的影响。

The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.

机构信息

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse University Cancer Institute (IUCT) - Oncopole, Toulouse, France.

Gynecological Oncology Unit, La Paz Investigation Institute (IdiPAZ), La Paz University Hospital, Madrid, Spain.

出版信息

Gynecol Oncol. 2022 Jul;166(1):8-17. doi: 10.1016/j.ygyno.2022.05.002. Epub 2022 May 12.

DOI:10.1016/j.ygyno.2022.05.002
PMID:35568582
Abstract

OBJECTIVE

To assess the impact on survival of major postoperative complications and to identify the factors associated with these complications in patients with advanced ovarian cancer after cytoreductive surgery.

METHODS

We designed a retrospective multicenter study collecting data from patients with IIIC-IV FIGO Stage ovarian cancer who had undergone either primary debulking surgery (PDS), early interval debulking surgery (IDS) after 3-4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery (DDS) after 6 cycles, with minimal or no residual disease, from January 2008 to December 2015. Univariable and multivariable analyses were conducted to identify factors associated with major surgical complications (≥Grade 3). We assessed disease-free survival (DFS) and overall survival (OS) rates according to the occurrence of major postoperative complications.

RESULTS

549 women were included. The overall rate of major surgical complications was 22.4%. Patients who underwent PDS had a higher rate of major complications (28.6%) than patients who underwent either early IDS (23.2%) or DDS (14.0%). Multivariable analysis revealed that extensive peritonectomy and surgical timing were associated with the occurrence of major complications. Median DFS and OS were 16.9 months (95%CI = [13.7-18.4]) and 48.0 months (95%CI = [37.2-73.1]) for the group of patients with major complications, and 20.1 months (95%CI = [18.6-22.4]) and 56.7 months (95%CI = [51.2-70.4]) for the group without major complications. Multivariable analysis revealed that major surgical complications were significantly associated with DFS, but not with OS.

CONCLUSIONS

Patients who experienced major surgical complications had reduced DFS, compared with patients without major morbidity. Extensive peritonectomy and surgical timing were predictive factors of postoperative morbidity.

摘要

目的

评估主要术后并发症对生存的影响,并确定在接受新辅助化疗 3-4 周期后行初次肿瘤细胞减灭术(PDS)、早期间隔肿瘤细胞减灭术(IDS)或 6 周期后行延迟肿瘤细胞减灭术(DDS)且残余病灶微小或无残余病灶的晚期卵巢癌患者中与这些并发症相关的因素。

方法

我们设计了一项回顾性多中心研究,收集了 2008 年 1 月至 2015 年 12 月期间接受初次肿瘤细胞减灭术(PDS)、新辅助化疗 3-4 周期后行早期间隔肿瘤细胞减灭术(IDS)或 6 周期后行延迟肿瘤细胞减灭术(DDS)且残余病灶微小或无残余病灶的 IIIC-IV 期FIGO 卵巢癌患者的资料。采用单变量和多变量分析确定与主要手术并发症(≥3 级)相关的因素。我们根据主要术后并发症的发生情况评估无病生存(DFS)和总生存(OS)率。

结果

共纳入 549 例患者。主要手术并发症的总体发生率为 22.4%。行 PDS 的患者主要并发症发生率(28.6%)高于行早期 IDS(23.2%)或 DDS(14.0%)的患者。多变量分析显示,广泛腹膜切除术和手术时机与主要并发症的发生有关。主要并发症组的中位 DFS 和 OS 分别为 16.9 个月(95%CI=[13.7-18.4])和 48.0 个月(95%CI=[37.2-73.1]),无主要并发症组的中位 DFS 和 OS 分别为 20.1 个月(95%CI=[18.6-22.4])和 56.7 个月(95%CI=[51.2-70.4])。多变量分析显示,主要手术并发症与 DFS 显著相关,但与 OS 无关。

结论

与无主要并发症患者相比,发生主要手术并发症的患者 DFS 降低。广泛腹膜切除术和手术时机是术后发病率的预测因素。

相似文献

1
The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.主要术后并发症对卵巢癌细胞减灭术后复发和长期生存的影响。
Gynecol Oncol. 2022 Jul;166(1):8-17. doi: 10.1016/j.ygyno.2022.05.002. Epub 2022 May 12.
2
A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.晚期卵巢癌完全细胞减灭术后肿瘤负担、手术时机和复杂性的预后影响的多变量分析。
Gynecol Oncol. 2020 Sep;158(3):614-621. doi: 10.1016/j.ygyno.2020.06.495. Epub 2020 Jul 22.
3
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.在晚期上皮性卵巢癌中,初次肿瘤细胞减灭术时的微小残留病灶与间隔性肿瘤细胞减灭术时的完全肿瘤切除相比:一项生存分析。
Gynecol Oncol. 2020 Apr;157(1):209-213. doi: 10.1016/j.ygyno.2020.01.010. Epub 2020 Jan 15.
4
Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.前瞻性手术与新辅助化疗后间隔减瘤手术治疗 IIIC 期和 IV 期卵巢癌患者的研究,SGOG SUNNY(SOC-2)试验方案。
J Gynecol Oncol. 2020 Sep;31(5):e86. doi: 10.3802/jgo.2020.31.e86.
5
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗:生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
6
[Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].[晚期卵巢癌患者新辅助化疗后行间隔减瘤手术的预后获益相关因素分析]
Zhonghua Fu Chan Ke Za Zhi. 2021 Jun 25;56(6):385-392. doi: 10.3760/cma.j.cn112141-20201207-00871.
7
Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.晚期卵巢癌患者复发模式对基于手术时机的复发后生存的影响。
Int J Gynecol Cancer. 2023 Jan 3;33(1):50-56. doi: 10.1136/ijgc-2022-003985.
8
Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis.预测卵巢癌细胞减灭术后术后发病率的因素:系统评价和荟萃分析。
J Gynecol Oncol. 2022 Jul;33(4):e53. doi: 10.3802/jgo.2022.33.e53. Epub 2022 Jun 7.
9
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.新辅助化疗后间隔减瘤手术治疗晚期上皮性卵巢癌:GOTIC-019 研究。
Int J Clin Oncol. 2023 Jun;28(6):804-815. doi: 10.1007/s10147-023-02329-7. Epub 2023 May 4.
10
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer.肿瘤负担和根治性手术对卵巢癌直接手术、早期间隔手术和延迟减瘤手术之间生存差异的影响。
J Gynecol Oncol. 2021 Nov;32(6):e78. doi: 10.3802/jgo.2021.32.e78. Epub 2021 Aug 13.

引用本文的文献

1
Perioperative Risk Prediction in Major Gynaecological Oncology Surgery: A National Diagnostic Survey of UK Clinical Practice.妇科肿瘤大手术围手术期风险预测:英国临床实践的全国性诊断调查
Diagnostics (Basel). 2025 Jul 6;15(13):1723. doi: 10.3390/diagnostics15131723.
2
Postoperative Complications After Cytoreductive Surgery for Advanced Ovarian Carcinoma: A Single-Center Analysis Exploring the Value of the Comprehensive Complication Index and the Predictors of High Complications Burden.晚期卵巢癌肿瘤细胞减灭术后的并发症:一项探索综合并发症指数价值及高并发症负担预测因素的单中心分析
Ann Surg Oncol. 2025 Jun 24. doi: 10.1245/s10434-025-17619-9.
3
The impact of preoperative immunonutritional status on postoperative complications in ovarian cancer.
术前免疫营养状况对卵巢癌术后并发症的影响。
J Ovarian Res. 2025 Apr 29;18(1):88. doi: 10.1186/s13048-025-01624-3.
4
Adjuvant chemotherapy after radical hysterectomy yields comparable outcomes to chemoradiation for stage IB2-IIB and IIIC1-2 cervical cancer: a single-center retrospective study.根治性子宫切除术后辅助化疗与同步放化疗治疗IB2-IIB期和IIIC1-2期宫颈癌的疗效相当:一项单中心回顾性研究
J Gynecol Oncol. 2025 Sep;36(5):e82. doi: 10.3802/jgo.2025.36.e82. Epub 2025 Mar 3.
5
Effect of Whey Protein Supplementation on Postoperative Outcomes After Gynecological Cancer Surgery: A Randomized Controlled Trial.补充乳清蛋白对妇科癌症手术后结局的影响:一项随机对照试验。
World J Oncol. 2025 Feb;16(1):70-82. doi: 10.14740/wjon1990. Epub 2025 Jan 2.
6
The mechanism of sevoflurane affecting ovarian cancer cell proliferation and migration by regulating RNA methylase TRDMT1 to activate the β-catenin pathway.七氟醚通过调节RNA甲基化酶TRDMT1激活β-连环蛋白通路影响卵巢癌细胞增殖和迁移的机制。
Cell Biol Toxicol. 2024 Dec 4;40(1):108. doi: 10.1007/s10565-024-09941-x.